Replies to post #933 on Revance Therapeutics Inc (RVNC)

[DewDiligence]

Re: Jefferies conference/EOLS/Hugel/etc.

I didn't [Lauren Silvernail] say that…

She said it during the breakout session following the webcast; one had to be there in person to hear it.

…what of the take on the call of a Hugel toxin approval?

I commented on Hugel’s toxin in #msg-147646851; inasmuch as Hugel has run clinical trials only in Korea, it’s not a serious concern at this time for RVNC investors, IMO.

Last point from the call was affirmation from EOLS that the bundling discount clients get from AGN (by buying both fillers/Botox together) could make things difficult to gain share because all EOLS has is a toxin.

AGN’s bundle pricing is an impediment for EOLS because Jeuveau is undifferentiated from Botox. It should be much less of a concern for RVNC.

EOLS said on the call they won't break even for 2 years.

Again, Jeuveau is an undifferentiated product and it won’t get garner any off-label sales in therapeutic indications. Moroever, there are some problems with EOLS' business model due to the CoI of having its injectors being affiliated investors (#msg-144974747).

…Assuming RVNC was on a similar path…

RVNC’s sales ramp should be considerably steeper than EOLS’ for the various reasons mentioned above.